Similar articles

• When can the patient with deep venous thrombosis begin to ambulate?

  Aldrich D, Hunt DP. Aldrich D, et al. Phys Ther. 2004 Mar;84(3):268-73. Phys Ther. 2004. PMID: 14984299 Review. No abstract available.
• Empiric use of anticoagulant and fibrinolytic agents in surgical therapy.

  Laufman H. Laufman H. Am Surg. 1974 Jan;40(1):15-21. Am Surg. 1974. PMID: 4808618 No abstract available.
• [Low-molecular-weight heparin - enoxaparin (clexane) in the prevention of thromboembolic complications in surgical patients].

  Zabolotskikh IB, Sin'kov SV, Klevko VA. Zabolotskikh IB, et al. Anesteziol Reanimatol. 2001 Mar-Apr;(2):70-5. Anesteziol Reanimatol. 2001. PMID: 11494909 Review. Russian. No abstract available.
• [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].

  Ruiz Manzano J, Monreal M. Ruiz Manzano J, et al. Med Clin (Barc). 1998 Nov 28;111(18):697-9. Med Clin (Barc). 1998. PMID: 9887434 Spanish. No abstract available.
• [Efficacy and tolerance of the low molecular weight heparin fraction CY 216 in preventing postoperative venous thromboembolism].

  Kakkar VV. Kakkar VV. Med Klin Suppl. 1986 Oct;3:13-6. Med Klin Suppl. 1986. PMID: 3550366 Clinical Trial. German. No abstract available.